Genprex
GNPX
10 hedge funds and large institutions have $79.7K invested in Genprex in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
25% more funds holding
Funds holding: 8 → 10 (+2)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
84% less capital invested
Capital invested by funds: $510K → $79.7K (-$431K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$63K |
| 2 |
VF
Virtu Financial
New York
|
+$55.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$25.9K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$23.5K |
| 5 |
HF
HRT Financial
New York
|
+$17.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$411K |
| 2 |
BBHC
Brown Brothers Harriman & Co
New York
|
-$4.71K |
| 3 |
BlackRock
New York
|
-$1.24K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$1.24K |
GNPX Hedge Fund Activity: Q3 2024 in Review
10 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q3 2024, worth a combined $79.7K — down 84% from $510K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GNPX positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $63K. The largest seller was Armistice Capital, exiting entirely with an estimated $411K sold.
- 10 institutional investors held Genprex (GNPX) as of Q3 2024, up from 8 in Q2 2024.
- Funds reported $79.7K of Genprex stock for Q3 2024, down 84% quarter-over-quarter.
- 5 funds opened new Genprex positions in Q3 2024 and 3 closed out, a net change of +2 holders.
- The largest Genprex buyer in Q3 2024 was UBS Group, an estimated $63K added.
- The largest Genprex seller in Q3 2024 was Armistice Capital, an estimated $411K sold.
Based on aggregated 13F filings for Q3 2024.